Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $53.6 million.

  • Mereo BioPharma Group's Liabilities and Shareholders Equity fell 39.60% to $53.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $260.9 million, marking a year-over-year decrease of 15.09%. This contributed to the annual value of $76.4 million for FY2024, which is 14.87% up from last year.
  • As of Q3 2025, Mereo BioPharma Group's Liabilities and Shareholders Equity stood at $53.6 million, which was down 14.42% from $62.6 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Liabilities and Shareholders Equity ranged from a high of $202.6 million in Q2 2021 and a low of $53.6 million during Q3 2025.
  • Its 3-year average for Liabilities and Shareholders Equity is $71.0 million, with a median of $67.4 million in 2023.
  • As far as peak fluctuations go, Mereo BioPharma Group's Liabilities and Shareholders Equity spiked by 105.02% in 2021, and later tumbled by 54.57% in 2022.
  • Over the past 5 years, Mereo BioPharma Group's Liabilities and Shareholders Equity (Quarterly) stood at $170.4 million in 2021, then slumped by 54.57% to $77.4 million in 2022, then fell by 14.10% to $66.5 million in 2023, then increased by 14.87% to $76.4 million in 2024, then crashed by 39.60% to $53.6 million in 2025.
  • Its Liabilities and Shareholders Equity was $53.6 million in Q3 2025, compared to $62.6 million in Q2 2025 and $68.3 million in Q1 2025.